Paper Contents
Abstract
As the US population ages, Parkinsons disease, the second most prevalent progressive neurodegenerative illness affecting older persons in the country, is expected to become more widespread. Idiopathic Parkinsons disease, which develops from a pathophysiologic loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain and the development of neuronal Lowy bodies, is linked to risk factors such as aging, family history, exposure to pesticides, and environmental chemicals (think synthetic heroin use, for example). The cause(s) of it all are(are) unknown. Parkinsons disease (PD) patients are typically characterized by rest tremor, stiffness, bradykinesia, and stooping posture in addition to other motor and non-motor symptoms.Moreover, neurobehavioral disorders (such as anxiety and depression), dementia, and autonomic dysfunction (such as orthostatic and hyperhidrosis) have been linked to Parkinsons disease (PD). Innovative surgical procedures like deep brain stimulation (DBS) and medicinal pharmaceutical therapy have proliferated in recent decades. But there is currently a lack of a conclusive disease-modifying treatment. There has been little progress in the development and testing of experimental medicines. It is crucial for caregivers, medical professionals, and patients themselves to understand strategies that provide the best possible quality of life for people with Parkinsons disease.
Copyright
Copyright © 2025 Mr.Shubham G.Shinde. This is an open access article distributed under the Creative Commons Attribution License.
